Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.
Journal: The Lancet. Infectious diseases
Published: September 11, 2025
Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays.
Journal: Clinical chemistry and laboratory medicine
Published: May 19, 2025
Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment.
Journal: Frontiers in antibiotics
Published: February 11, 2025
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
Journal: The Lancet. Infectious diseases
Published: April 26, 2024
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
Journal: Antimicrobial agents and chemotherapy
Published: May 23, 2023
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
Journal: Antimicrobial agents and chemotherapy
Published: March 06, 2023
Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.
Journal: BMC infectious diseases
Published: December 22, 2021
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: June 12, 2020
Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
Journal: PLoS medicine
Published: October 04, 2018
Corrigendum to "Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis" [Tuberculosis 108 (January 2018) 186-194].
Journal: Tuberculosis (Edinburgh, Scotland)
Published: April 05, 2018
Last Updated: 09/26/2026